These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Structural insights into the functional diversity of the CDK-cyclin family. Wood DJ; Endicott JA Open Biol; 2018 Sep; 8(9):. PubMed ID: 30185601 [TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions. Klein MA Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419 [TBL] [Abstract][Full Text] [Related]
8. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Iavarone A; Massagué J Nature; 1997 May; 387(6631):417-22. PubMed ID: 9163429 [TBL] [Abstract][Full Text] [Related]
9. Characterization of the interactions between human cdc25C, cdks, cyclins and cdk-cyclin complexes. Morris MC; Divita G J Mol Biol; 1999 Feb; 286(2):475-87. PubMed ID: 9973565 [TBL] [Abstract][Full Text] [Related]
10. Two different bindings of p21 Cdk inhibitor to cyclin/Cdk complex. Nakanishi M; Kagawa Y; Takahashi H; Matsushime H Leukemia; 1997 Apr; 11 Suppl 3():356-7. PubMed ID: 9209388 [TBL] [Abstract][Full Text] [Related]
11. The cyclin box and C-terminus of cyclins A and E specify CDK activation and substrate specificity. Horton LE; Templeton DJ Oncogene; 1997 Jan; 14(4):491-8. PubMed ID: 9053846 [TBL] [Abstract][Full Text] [Related]
12. Structural dissection of cyclin dependent kinases regulation and protein recognition properties. Lolli G Cell Cycle; 2010 Apr; 9(8):1551-61. PubMed ID: 20372077 [TBL] [Abstract][Full Text] [Related]
13. Purification of Cyclin-Dependent Kinase Fusion Complexes for In Vitro Analysis. Kõivomägi M Methods Mol Biol; 2021; 2329():95-109. PubMed ID: 34085218 [TBL] [Abstract][Full Text] [Related]
14. Cyclin E-CDK2 is a regulator of p27Kip1. Sheaff RJ; Groudine M; Gordon M; Roberts JM; Clurman BE Genes Dev; 1997 Jun; 11(11):1464-78. PubMed ID: 9192873 [TBL] [Abstract][Full Text] [Related]
15. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity. Premnath PN; Craig SN; Liu S; Anderson EL; Grigoroudis AI; Kontopidis G; Perkins TL; Wyatt MD; Pittman DL; McInnes C J Med Chem; 2015 Jan; 58(1):433-42. PubMed ID: 25454794 [TBL] [Abstract][Full Text] [Related]
16. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division. Lacy ER; Wang Y; Post J; Nourse A; Webb W; Mapelli M; Musacchio A; Siuzdak G; Kriwacki RW J Mol Biol; 2005 Jun; 349(4):764-73. PubMed ID: 15890360 [TBL] [Abstract][Full Text] [Related]
18. Function of hybrid human-yeast cyclin-dependent kinases in Saccharomyces cerevisiae. Bitter GA Mol Gen Genet; 1998 Oct; 260(1):120-30. PubMed ID: 9829836 [TBL] [Abstract][Full Text] [Related]
19. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors. Kalra S; Joshi G; Munshi A; Kumar R Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822 [TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Roskoski R Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]